• Filiberto Cedeno-Laurent, Elisha M Singer, Maria Wysocka, Bernice M Benoit, Carmela C Vittorio, Ellen J Kim, Gil Yosipovitch, and Alain H Rook.
• Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: filiberto.cedenolaurent@uphs.upenn.edu.
• Clin. Immunol. 2015 May 1;158(1):1-7.

AbstractPruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.Copyright © 2015 Elsevier Inc. All rights reserved.

46 keywords...

hide…